Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)
Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children
Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.
This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.
Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.
A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Francoise SCHMITT, MD
- Numero di telefono: +33 2 41 35 42 90
- Email: FrSchmitt@chu-angers.fr
Backup dei contatti dello studio
- Nome: Josue Rakotonjanahary
- Numero di telefono: +33 2 41 35 57 40
- Email: JoRakotonjanahary@chu-angers.fr
Luoghi di studio
-
-
-
Amiens, Francia, 80054
- CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
-
Contatto:
- Philippe BUISSON, MD
- Numero di telefono: +33 3 22 08 75 60
- Email: buisson.philippe@chu-amiens.fr
-
Investigatore principale:
- Philippe BUISSON, MD
-
Angers, Francia, 49933
- CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
-
Contatto:
- Francoise SCHMITT, MD
- Numero di telefono: 2 41 35 42 90
- Email: FrSchmitt@chu-angers.fr
-
Contatto:
-
Investigatore principale:
- francoise SCHMITT, MD
-
Clermont-Ferrand, Francia, 63003
- CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
-
Contatto:
- Carole Egron, MD
- Numero di telefono: +33 4 73 75 00 24
- Email: cegron@chu-clermontferrand.fr
-
Investigatore principale:
- Carole EGRON, MD
-
Dijon, Francia, 21000
- CHU Dijon, Service de chirurgie pédiatrique
-
Contatto:
- Michel FRANCOIS, MD
- Numero di telefono: +33 3 80 28 14 35
- Email: michel.françois@chu-dijon.fr
-
Investigatore principale:
- Michel FRANCOIS, MD
-
Grenoble, Francia, 38700
- CHU Grenoble, Service de chirurgie pédiatrique
-
Contatto:
- Pierre-Yves RABATTU, MD
- Numero di telefono: +33 4 76 76 59 00
- Email: pyrabattu@chu-grenoble.fr
-
Investigatore principale:
- Pierre-Yves RABATTU, MD
-
Le Kremlin-Bicêtre, Francia, 94275
- Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
-
Contatto:
- Khadidja KHADIR, MD
- Numero di telefono: +33 1 45 21 21 21
- Email: khadidja.khadir@aphp.fr
-
Investigatore principale:
- Khadidja KHADIR, MD
-
Lyon, Francia, 69677
- Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
-
Contatto:
- Nicolas CARON, MD
- Numero di telefono: +33 4 72 35 70 50
- Email: nicolas.caron@chu-lyon.fr
-
Investigatore principale:
- Nicolas CARON, MD
-
Nantes, Francia, 44093
- CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
-
Contatto:
- Audrey GUINOT, MD
- Numero di telefono: +33 2 40 08 35 85
- Email: audrey.guinot@chu-nantes.fr
-
Investigatore principale:
- Audrey GUINOT, MD
-
Paris, Francia, 75015
- Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
-
Contatto:
- Rola ABOU TAAM, MD
- Numero di telefono: +33 1 44 38 15 65
- Email: rola.aboutaam@aphp.fr
-
Investigatore principale:
- Rola ABOU TAAM, MD
-
Strasbourg, Francia, 67098
- CHU Strasbourg, Service de chirurgie pédiatrique
-
Contatto:
- Isabelle TALON, MD
- Numero di telefono: +33 3 88 12 73 17
- Email: isabelle.talon@chru-strasbourg.fr
-
Toulouse, Francia, 31059
- CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
-
Contatto:
- Aurélie LE MANDAT, MD
- Numero di telefono: +33 5 34 55 85 44
- Email: lemandat.a@chu-toulouse.fr
-
Investigatore principale:
- Aurelie LE MANDAT, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).
Descrizione
For thoracoscopy group:
Inclusion Criteria:
- Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Conversion from thoracoscopy to thoracotomy during the procedure
- Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
- For Thoracotomy group*:
Inclusion Criteria :
--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
- Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification
For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.
*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).
**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
thoracoscopy group
minimally invasive surgical approach |
|
thoracotomy arm
conventionnal surgical approach |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Lasso di tempo: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022. |
Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
to evaluate the importance of restrictive syndrome
Lasso di tempo: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]). |
importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
|
Looking for other respiratory parameters
Lasso di tempo: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present |
the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
|
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Lasso di tempo: until spirometry is completed, within a maximum period of 2 years
|
The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10). |
until spirometry is completed, within a maximum period of 2 years
|
|
rate of postoperative complications and any necessary reoperations
Lasso di tempo: up to 2 years after the multidisciplinary consultation
|
The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries. |
up to 2 years after the multidisciplinary consultation
|
|
Respiratory-related quality of life during childhood
Lasso di tempo: up to 2 years after the multidisciplinary consultation
|
It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10). |
up to 2 years after the multidisciplinary consultation
|
|
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Lasso di tempo: through study completion, within a maximum of 24 months
|
The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis). |
through study completion, within a maximum of 24 months
|
|
to assess the mortality rate
Lasso di tempo: through study completion, an average 7 years
|
The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry). |
through study completion, an average 7 years
|
|
Looking for lung volumes variations
Lasso di tempo: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Lung volume variations will be measured by dynamic respiratory MRI data |
the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 49RC25_0432
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .